Emergent BioSolutions (NYSE:EBS) Shares Down 7% – Here’s Why

Emergent BioSolutions Inc. (NYSE:EBS) shares traded down 7% on Monday . The company traded as low as $10.12 and last traded at $10.46. 376,780 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 954,547 shares. The stock had previously closed at $11.25.

Analyst Ratings Changes

Several brokerages recently issued reports on EBS. StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Friday, January 24th. Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, January 21st.

Emergent BioSolutions Stock Up 2.2 %

The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock’s fifty day simple moving average is $9.63 and its two-hundred day simple moving average is $9.30. The stock has a market capitalization of $580.65 million, a P/E ratio of -2.61 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.88. The company had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter in the previous year, the firm posted ($1.44) earnings per share. As a group, research analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Emergent BioSolutions

Institutional investors and hedge funds have recently made changes to their positions in the stock. Wolverine Asset Management LLC bought a new stake in Emergent BioSolutions in the fourth quarter valued at approximately $1,303,000. Hussman Strategic Advisors Inc. acquired a new stake in shares of Emergent BioSolutions during the fourth quarter worth $201,000. New York State Common Retirement Fund raised its stake in Emergent BioSolutions by 41.7% during the fourth quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company’s stock worth $2,928,000 after buying an additional 90,113 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Emergent BioSolutions in the fourth quarter valued at $1,831,000. Finally, Assenagon Asset Management S.A. lifted its holdings in Emergent BioSolutions by 3.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock valued at $7,328,000 after buying an additional 24,985 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.